Efficacy and Safety of Bevacizumab for Treating Glioblastoma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled Trials

Abstract

Objective

To fully investigate the efficacy and safety of bevacizumab for glioblastoma.

Methods

Databases were searched for phase II/III randomized controlled trials treated with bevacizumab.

Results

Bevacizumab significantly improved the PFS in glioblastoma patients, but did not prolong OS. PFS was significantly prolonged in both first-line and second-line treatment. Bevacizumab plus temozolomide was correlated with improved PFS for patients with different MGMT methylation status. Bevacizumab could increase the risk of hypertension, proteinuria, thromboembolic, and infection. Hypertension should be well concerned.

Conclusions

Bevacizumab-containing regimen can significantly improve PFS, but did not prolong OS.

Keywords:

• Bevacizumab
• anti-VEGF antibody
• glioblastoma
• efficacy
• meta-analysis

Author contributions

XiaoHong Xie and Shangyi Bao conceived and designed the study. Liuying Li and XiaoJun Fu wrote the main manuscript text. Hong Zhao and XiaoHong Xie extracted and reviewed the data. Liuying Li and XiaoJun Fu analyzed the data.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.